Objective:

To investigate the potential of losartan as a therapeutic agent for intestinal fibrosis in Crohn’s disease, a significant complication that often leads to strictures and invasive treatments.

Key Findings:

• Increased angiotensinogen and decreased ACE and AT1 in inflamed gut mucosa of CD patients.
• Losartan suppressed pro-fibrotic molecules and inhibited fibroblast-to-myofibroblast differentiation in vitro.
• In SAMP mice, losartan reduced inflammation and fibrosis severity, and prevented fibrosis relapse after steroid-induced remission.

Interpretation:

Losartan effectively targets the RAS pathway, reducing intestinal inflammation and fibrosis, suggesting its potential as a therapeutic strategy for fibrostenosing Crohn’s disease, with implications for clinical practice.

Limitations:

• Lack of standardized scoring system for intestinal fibrosis in humans and mice, which may affect comparability.
• Observational studies may have confounding factors affecting causal relationships, necessitating cautious interpretation.

Conclusion:

Losartan shows promise as a cost-effective and safe adjunctive therapy for managing fibrostenosing Crohn’s disease through RAS inhibition, highlighting the need for further research to validate these findings.